HLTH vs. AXDX, TLIS, OMIC, TBIO, PRPO, RPID, BNGO, FLGC, TXMD, and DMTK
Should you be buying Cue Health stock or one of its competitors? The main competitors of Cue Health include Accelerate Diagnostics (AXDX), Talis Biomedical (TLIS), Singular Genomics Systems (OMIC), Telesis Bio (TBIO), Precipio (PRPO), Rapid Micro Biosystems (RPID), Bionano Genomics (BNGO), Flora Growth (FLGC), TherapeuticsMD (TXMD), and DermTech (DMTK). These companies are all part of the "medical" sector.
Cue Health (NASDAQ:HLTH) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
In the previous week, Accelerate Diagnostics had 8 more articles in the media than Cue Health. MarketBeat recorded 8 mentions for Accelerate Diagnostics and 0 mentions for Cue Health. Cue Health's average media sentiment score of -0.09 beat Accelerate Diagnostics' score of -0.25 indicating that Cue Health is being referred to more favorably in the media.
45.5% of Cue Health shares are owned by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are owned by institutional investors. 12.5% of Cue Health shares are owned by insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Accelerate Diagnostics has lower revenue, but higher earnings than Cue Health. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Cue Health, indicating that it is currently the more affordable of the two stocks.
Accelerate Diagnostics has a net margin of -454.95% compared to Cue Health's net margin of -526.48%. Accelerate Diagnostics' return on equity of 0.00% beat Cue Health's return on equity.
Cue Health has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.
Cue Health presently has a consensus price target of $3.00, indicating a potential upside of 2,225.58%. Accelerate Diagnostics has a consensus price target of $1.00, indicating a potential upside of 12.36%. Given Cue Health's higher probable upside, equities analysts plainly believe Cue Health is more favorable than Accelerate Diagnostics.
Accelerate Diagnostics received 353 more outperform votes than Cue Health when rated by MarketBeat users. Likewise, 63.44% of users gave Accelerate Diagnostics an outperform vote while only 7.14% of users gave Cue Health an outperform vote.
Summary
Accelerate Diagnostics beats Cue Health on 10 of the 18 factors compared between the two stocks.
Get Cue Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Health Competitors List
Related Companies and Tools
